

Thai Nakin Hospital Public Company Limited
and its subsidiary
Review report interim financial information
For the three-month and six-month periods ended
31 January 2024

Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Thai Nakarin Hospital Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Thai Nakarin Hospital Public Company Limited and its subsidiary ("the Group") as at 31 January 2024, and the related consolidated statements of comprehensive income, changes in shareholders' equity and cash flows for the three-month and six-month periods then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Thai Nakarin Hospital Public Company Limited for the same period (collectively "interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 Interim Financial Reporting. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 Interim Financial Reporting.

Samran Taengcham

Certified Public Accountant (Thailand) No. 8021

EY Office Limited

Bangkok: 14 March 2024

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of financial position

As at 31 January 2024

(Unit: Thousand Baht)

	Note	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
		31 January	31 July	31 January	31 July
		2024	2023	2024	2023
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Assets					
Current assets					
Cash and cash equivalents	3	1,403,581	1,297,934	1,401,988	1,296,171
Trade and other receivables	2, 4	211,900	211,890	211,720	211,709
Inventories		43,960	33,575	43,960	33,575
Other current financial assets	5	190,000	140,000	190,000	140,000
Other current assets		59	263	59	263
Total current assets		1,849,500	1,683,662	1,847,727	1,681,718
Non-current assets					
Investment in subsidiary	6	-	-	1,000	1,000
Property, plant and equipment	7	937,866	894,272	937,866	894,272
Intangible assets		9,688	10,402	9,688	10,402
Right-of-use assets	8	558,304	569,657	558,304	569,657
Deferred tax assets		24,801	23,020	24,801	23,020
Other non-current assets		264	133	264	133
Total non-current assets		1,530,923	1,497,484	1,531,923	1,498,484
Total assets		3,380,423	3,181,146	3,379,650	3,180,202

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of financial position (continued)

As at 31 January 2024

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		31 January 2024 (Unaudited but reviewed)	31 July 2023 (Audited)	31 January 2024 (Unaudited but reviewed)	31 July 2023 (Audited)
Liabilities and shareholders' equity					
Current liabilities					
Trade and other payables	9	210,586	185,074	210,536	184,924
Doctor fee payable		103,407	94,800	103,407	94,800
Income tax payable		44,576	29,023	44,576	29,023
Other current liabilities		45,368	33,242	45,367	33,242
Total current liabilities		403,937	342,139	403,886	341,989
Non-current liabilities					
Provision for long-term employee benefits		105,047	98,934	105,047	98,934
Other non-current financial liabilities		5,920	5,440	5,920	5,440
Total non-current liabilities		110,967	104,374	110,967	104,374
Total liabilities		514,904	446,513	514,853	446,363
Shareholders' equity					
Share capital					
Registered					
180,000,000 ordinary shares of Baht 1 each		180,000	180,000	180,000	180,000
Issued and fully paid-up					
180,000,000 ordinary shares of Baht 1 each		180,000	180,000	180,000	180,000
Share premium		20,538	20,538	20,538	20,538
Retained earnings					
Appropriated - statutory reserve		18,000	18,000	18,000	18,000
Unappropriated		2,646,981	2,516,095	2,646,259	2,515,301
Equity attributable to owners of the company		2,865,519	2,734,633	2,864,797	2,733,839
Total liabilities and shareholders' equity		3,380,423	3,181,146	3,379,650	3,180,202

The accompanying notes are an integral part of the financial statements.

Directors

(Unaudited but reviewed)

Thai Nakaran Hospital Public Company Limited and its subsidiary

Statement of comprehensive income

For the three-month period ended 31 January 2024

(Unit: Thousand Baht except earnings per share expressed in Baht)

	Consolidated financial statements		Separate financial statements	
	31 January	31 January	31 January	31 January
Note	2024	2023	2024	2023
Profit and loss:				
Revenues				
Revenues from hospital operations	670,716	593,230	670,716	593,230
Other income	1,937	2,625	1,937	2,335
Total revenues	672,653	595,855	672,653	595,565
Expenses				
Cost of hospital operations and goods sold	480,797	447,853	480,797	447,666
Administrative expenses	62,424	43,266	62,387	43,228
Total expenses	543,221	491,119	543,184	490,894
Operating profit	129,432	104,736	129,469	104,671
Finance income	5,200	2,536	5,195	2,534
Profit before income tax expenses	134,632	107,272	134,664	107,205
Income tax expenses	10 (26,049)	(20,431)	(26,049)	(20,465)
Profit for the period	108,583	86,841	108,615	86,740
Other comprehensive income:				
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	108,583	86,841	108,615	86,740
Basic earnings per share				
Profit (Baht)	0.60	0.48	0.60	0.48
Weighted average number of ordinary shares (Thousand shares)	180,000	180,000	180,000	180,000

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Thai Nakarin Hospital Public Company Limited and its subsidiary
Statement of comprehensive income
For the six-month period ended 31 January 2024

(Unit: Thousand Baht except earnings per share expressed in Baht)

	Consolidated financial statements		Separate financial statements	
	31 January	31 January	31 January	31 January
Note	2024	2023	2024	2023
Profit and loss:				
Revenues				
Revenues from hospital operations	1,366,704	1,190,462	1,366,704	1,190,462
Other income	3,944	7,666	3,944	6,893
Total revenues	1,370,648	1,198,128	1,370,648	1,197,355
Expenses				
Cost of hospital operations and goods sold	959,597	875,994	959,597	875,648
Administrative expenses	124,243	127,237	124,166	127,160
Total expenses	1,083,840	1,003,231	1,083,763	1,002,808
Operating profit	286,808	194,897	286,885	194,547
Finance income	9,257	3,849	9,252	3,847
Profit before income tax expenses	296,065	198,746	296,137	198,394
Income tax expenses	10 (57,179)	(37,703)	(57,179)	(37,695)
Profit for the period	238,886	161,043	238,958	160,699
Other comprehensive income:				
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	238,886	161,043	238,958	160,699
Basic earnings per share				
Profit (Baht)	1.33	0.89	1.33	0.89
Weighted average number of ordinary shares (Thousand shares)	180,000	180,000	180,000	180,000

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of changes in shareholders' equity

For the six-month period ended 31 January 2024

(Unit: Thousand Baht)

	Consolidated financial statements				Total shareholders' equity
	Issued and paid-up share capital	Share premium	Retained earnings		
			Appropriated - statutory reserve	Unappropriated	
Balance as at 1 August 2022	180,000	20,538	18,000	2,265,462	2,484,000
Total comprehensive income for the period	-	-	-	161,043	161,043
Dividend paid (Note 11)	-	-	-	(108,000)	(108,000)
Balance as at 31 January 2023	180,000	20,538	18,000	2,318,505	2,537,043
Balance as at 1 August 2023	180,000	20,538	18,000	2,516,095	2,734,633
Total comprehensive income for the period	-	-	-	238,886	238,886
Dividend paid (Note 11)	-	-	-	(108,000)	(108,000)
Balance as at 31 January 2024	180,000	20,538	18,000	2,646,981	2,865,519

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of changes in shareholders' equity

For the six-month period ended 31 January 2024

(Unit: Thousand Baht)

	Separate financial statements				Total shareholders' equity
	Issued and paid-up share capital	Share premium	Retained earnings Appropriated - statutory reserve	Unappropriated	
Balance as at 1 August 2022	180,000	20,538	18,000	2,264,940	2,483,478
Total comprehensive income for the period	-	-	-	160,699	160,699
Dividend paid (Note 11)	-	-	-	(108,000)	(108,000)
Balance as at 31 January 2023	<u>180,000</u>	<u>20,538</u>	<u>18,000</u>	<u>2,317,639</u>	<u>2,536,177</u>
Balance as at 1 August 2023	180,000	20,538	18,000	2,515,301	2,733,839
Total comprehensive income for the period	-	-	-	238,958	238,958
Dividend paid (Note 11)	-	-	-	(108,000)	(108,000)
Balance as at 31 January 2024	<u>180,000</u>	<u>20,538</u>	<u>18,000</u>	<u>2,646,259</u>	<u>2,864,797</u>

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of cash flows

For the six-month period ended 31 January 2024

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	31 January	31 January	31 January	31 January
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Cash flows from operating activities				
Profit before tax	296,065	198,746	296,137	198,394
Adjustments to reconcile profit before tax to net cash provided by (paid from) operating activities:				
Depreciation and amortisation expenses	61,421	57,043	61,421	57,043
Allowance for expected credit losses	2,899	14,589	2,899	14,589
Long-term employee benefit expenses	7,349	6,961	7,349	6,961
(Gain) loss on disposals of equipment	170	(2,059)	170	(2,059)
Interest income	<u>(9,257)</u>	<u>(3,847)</u>	<u>(9,252)</u>	<u>(3,847)</u>
Profit from operating activities before changes in operating assets and liabilities	358,647	271,433	358,724	271,081
Decrease (increase) in operating assets				
Trade and other receivables	(2,639)	78,517	(2,640)	78,492
Inventories	(10,385)	(7,603)	(10,385)	(7,603)
Other current assets	204	1,156	204	1,156
Other non-current assets	(131)	(47)	(131)	(47)
Increase (decrease) in operating liabilities				
Trade and other payables	22,774	935	22,874	1,890
Doctor fee payable	8,607	(9,047)	8,607	(9,047)
Other current liabilities	12,126	(1,692)	12,125	(1,692)
Provision for long-term employee benefits	(1,236)	(2,389)	(1,236)	(2,389)
Other non-current financial liabilities	<u>480</u>	<u>(4,022)</u>	<u>480</u>	<u>(4,022)</u>
Cash from operating activities	388,447	327,241	388,622	327,819
Cash paid for income tax	<u>(43,407)</u>	<u>(39,274)</u>	<u>(43,407)</u>	<u>(39,175)</u>
Net cash from operating activities	<u>345,040</u>	<u>287,967</u>	<u>345,215</u>	<u>288,644</u>

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of cash flows (continued)

For the six-month period ended 31 January 2024

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	31 January 2024	31 January 2023	31 January 2024	31 January 2023
Cash flows from investing activities				
Interest received	8,987	3,537	8,982	3,537
Decrease in other current financial assets	(50,000)	251,022	(50,000)	251,022
Cash paid for purchases of building improvement and equipment	(91,049)	(120,773)	(91,049)	(120,773)
Cash paid for purchase of intangible assets	(47)	(32)	(47)	(32)
Cash received from disposals of equipment	716	2,181	716	2,181
Net cash from (used in) investing activities	(131,393)	135,935	(131,398)	135,935
Cash flows from financing activities				
Dividend paid	(108,000)	(108,000)	(108,000)	(108,000)
Net cash used in financing activities	(108,000)	(108,000)	(108,000)	(108,000)
Net increase in cash and cash equivalents	105,647	315,902	105,817	316,579
Cash and cash equivalents at beginning of period	1,297,934	699,568	1,296,171	697,019
Cash and cash equivalents at end of period (Note 3)	1,403,581	1,015,470	1,401,988	1,013,598
Supplemental cash flows information				
Non-cash items				
Accounts payable - construction and equipment purchase	29,948	71,441	29,948	71,441

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary
Notes to consolidated interim financial statements
For the three-month and six-month periods ended 31 January 2024

1. General information

1.1 Corporate information

Thai Nakarin Hospital Public Company Limited (“the Company”) is a public company incorporated and domiciled in Thailand. The Company is principally engaged in hospital business. Its registered address is as follows:

Head office is located at No. 345 Thepparat Road, Bangna Nuea, Bangna, Bangkok.

Branch offices are located at No. 107/1 Moo 7 Siri Sothon Road, Bang Phra, Mueang Chachoengsao, Chachoengsao.

1.2 Basis for the preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, comprehensive income, changes in shareholders’ equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language financial statements.

1.3 Basis of consolidation

These interim consolidated financial statements include the financial statements of Thai Nakarin Hospital Public Company Limited and its subsidiary (“the Group”) and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 July 2023. There have been no changes in the structure of the subsidiary during the current period.

1.4 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 July 2023.

Financial reporting standards that became effective in the current year

The revised financial reporting standards which are effective for fiscal years beginning on or after 1 January 2023, do not have any significant impact on the Group's financial statements.

Financial reporting standards that will become effective for fiscal years beginning on or after 1 January 2024

The Federation of Accounting Professions issued a number of revised financial reporting standards and interpretations, which are effective for fiscal years beginning on or after 1 January 2024. The management of the Group is currently evaluating the impact of these standards to the financial statements in the years when they are adopted.

2. Related party transactions

During the periods, the Company had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon between the Company and those related parties.

	<u>Transfer pricing policy</u>
Revenue from hospital operations	Based on the price charged to normal customers
Rental income	Rates as stipulated in the agreements
Doctor fee expenses (directors and management)	Paid at the same rate as other doctors in the hospital
Medical welfare	Under the Company's regulations, medical welfare benefits are granted to directors, their spouses, children and parents, up to a specified amount per annum. These benefits exclude doctor fees, examinations conducted on other premises and special equipment charges

(Unaudited but reviewed)

(Unit: Thousand Baht)

For three-month periods ended 31 January

	Consolidated		Separate	
	financial statements		financial statements	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
<u>Transactions with related companies and persons</u>				
Revenue from hospital operations	11	13	11	13
Doctor fee expenses (directors and management)	1,338	2,416	1,338	2,416
Medical welfare	1,194	1,254	1,194	1,254

(Unit: Thousand Baht)

For six-month periods ended 31 January

	Consolidated		Separate	
	financial statements		financial statements	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
<u>Transactions with related companies and persons</u>				
Revenue from hospital operations	41	55	41	55
Doctor fee expenses (directors and management)	2,670	4,894	2,670	4,894
Medical welfare	2,329	2,338	2,329	2,338

The balances of accounts as at 31 January 2024 and 31 July 2023 between the Company and its related parties are as follows:

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 January 2024	31 July 2023	31 January 2024	31 July 2023
<u>Trade receivables - related parties</u>				
(Note 4)				
Related companies (related by common shareholders and directors)	5	23	5	23
Total trade receivables - related parties	5	23	5	23

(Unaudited but reviewed)

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 January	31 July	31 January	31 July
	2024	2023	2024	2023
<u>Doctor fee payable - related persons</u>				
Related persons (directors and management)	429	475	429	475
Total doctor fee payable - related persons	429	475	429	475

Directors and management's benefits

During the three-month and six-month periods ended 31 January 2024 and 2023, the Company had employee benefit expenses to its directors and management as below.

(Unit: Thousand Baht)

	For three-month periods		For six-month periods	
	ended 31 January		ended 31 January	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Short-term employee benefits	11,012	12,387	19,711	23,669
Post-employment benefits	931	628	1,862	1,261
Total	11,943	13,015	21,573	24,930

3. Cash and cash equivalents

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 January	31 July	31 January	31 July
	2024	2023	2024	2023
Cash	4,677	5,301	4,672	5,301
Bank deposits	1,398,904	1,292,633	1,397,316	1,290,870
Total cash and cash equivalents	1,403,581	1,297,934	1,401,988	1,296,171

As at 31 January 2024, bank deposits in savings accounts carried interests between 0.15 and 1.25 percent per annum (31 July 2023: between 0.15 and 1.25 percent per annum).

4. Trade and other receivables

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	31 January 2024	31 July 2023	31 January 2024	31 July 2023
<u>Trade receivables - related parties</u>				
Aged on the basis of due dates				
Not due yet	3	10	3	10
Past due				
Up to 3 months	2	4	2	4
6 - 12 months	-	9	-	9
Total trade receivables - related parties	<u>5</u>	<u>23</u>	<u>5</u>	<u>23</u>
<u>Trade receivables - unrelated parties</u>				
Aged on the basis of due dates				
Not yet due	92,625	88,718	92,625	88,718
Past due				
Up to 3 months	76,495	72,533	76,495	72,533
3 - 6 months	12,693	18,332	12,693	18,332
6 - 12 months	5,347	5,934	5,347	5,934
Over 12 months	27,598	32,084	27,598	32,084
Total trade receivables - unrelated parties	<u>214,758</u>	<u>217,601</u>	<u>214,758</u>	<u>217,601</u>
Less: Allowance for expected credit losses	<u>(16,051)</u>	<u>(13,152)</u>	<u>(16,051)</u>	<u>(13,152)</u>
Total trade receivables - unrelated parties - net	<u>198,707</u>	<u>204,449</u>	<u>198,707</u>	<u>204,449</u>
Total trade receivables - net	<u>198,712</u>	<u>204,472</u>	<u>198,712</u>	<u>204,472</u>
<u>Other receivables</u>				
Other receivables - unrelated parties	11,154	5,654	10,974	5,473
Accrued interest income	2,034	1,764	2,034	1,764
Total other receivables	<u>13,188</u>	<u>7,418</u>	<u>13,008</u>	<u>7,237</u>
Total trade and other receivables - net	<u>211,900</u>	<u>211,890</u>	<u>211,720</u>	<u>211,709</u>

5. Other current financial assets

As at 31 January 2024 and 31 July 2023, other current financial assets consisted of the following:

(Unit: Thousand Baht)

	Consolidated and separate financial statements			
	Other current financial assets		Interest rate (percent per annum)	
	31 January 2024	31 July 2023	31 January 2024	31 July 2023
Fixed deposits at financial institutions (12 months)	190,000	140,000	1.95 - 2.20	1.00 - 2.00
Total other current financial assets	<u>190,000</u>	<u>140,000</u>		

6. Investment in subsidiary

Details of investments in subsidiary as presented in the separate financial statements are as follows:

(Unit: Thousand Baht)

Company's name	Type of relation	Shareholding percentage		Cost	
		31 January 2024	31 July 2023	31 January 2024	31 July 2023
		(%)	(%)		
Local subsidiary					
Jatu Charoen Development Company Limited	Direct holding	99.97	99.97	1,000	1,000

On 13 December 2021, the Board of Directors' meeting No. 5/2021 resolved to approve the establishment of a new subsidiary, Jatu Charoen Development Company Limited, which is engaged in health establishment and hotel business, providing elderly and dependency care both onsite and offsite as well as distributions of medicines, supplement products, medical supplies and equipments. The subsidiary has a registered capital of 10,000 shares with a par value of Baht 100 per share, totaling Baht 1 million. The subsidiary registered the establishment with the Department of Business Development, the Ministry of Commerce on 18 February 2022.

(Unaudited but reviewed)

9. Trade and other payables

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements	financial statements	financial statements	financial statements
	31 January	31 July	31 January	31 July
	2024	2023	2024	2023
Trade payables - unrelated parties	117,475	101,985	117,475	101,985
Other payables - unrelated parties	20,367	18,505	20,367	18,505
Accounts payable - construction and equipment purchases	29,948	27,210	29,948	27,210
Accrued expenses	42,796	37,374	42,746	37,224
Total trade and other payables	<u>210,586</u>	<u>185,074</u>	<u>210,536</u>	<u>184,924</u>

10. Income tax

Interim corporate income tax is calculated on profit before income tax for the period, using the estimated effective tax rate for the year.

Income tax expenses for the three-month and six-month periods ended 31 January 2024 and 2023 are made up follows:

(Unit: Thousand Baht)

	For three-month periods ended 31 January			
	Consolidated		Separate	
	financial statements	financial statements	financial statements	financial statements
	2024	2023	2024	2023
Current income tax:				
Interim corporate income tax charge	26,570	19,470	26,570	19,504
Deferred tax:				
Relating to origination and reversal of temporary differences	(521)	961	(521)	961
Income tax expenses reported in the statements of comprehensive income	<u>26,049</u>	<u>20,431</u>	<u>26,049</u>	<u>20,465</u>

(Unaudited but reviewed)

(Unit: Thousand Baht)

For six-month periods ended 31 January

	Consolidated		Separate	
	financial statements	financial statements	financial statements	financial statements
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Current income tax:				
Interim corporate income tax charge	58,960	41,426	58,960	41,418
Deferred tax:				
Relating to origination and reversal of temporary differences	<u>(1,781)</u>	<u>(3,723)</u>	<u>(1,781)</u>	<u>(3,723)</u>
Income tax expenses reported in the statements of comprehensive income	<u>57,179</u>	<u>37,703</u>	<u>57,179</u>	<u>37,695</u>

11. Dividends

<u>Dividends</u>	<u>Approved by</u>	<u>Total dividends</u> (Million Baht)	<u>Dividend per share</u> (Baht)
Final dividends for 2022	Annual General Meeting of the shareholders on 17 November 2022	<u>108.0</u>	0.60
Total dividends for 2023		<u>108.0</u>	
Final dividends for 2023	Annual General Meeting of the shareholders on 22 November 2023	<u>108.0</u>	0.60
Total dividends for 2024		<u>108.0</u>	

12. Operating segment information

Operating segment information is reported in a manner consistent with the internal reporting the chief operating decision maker has received and regularly reviewed to make decisions about resources to be allocated to the segment and assess its performance. The chief operating decision maker has been identified as Executive Committee.

The one main reportable operating segment of the Company is the hospital business and the single geographical area of its operation is Thailand. Segment performance is evaluated based on operating profit or loss and is measured consistently with operating profit or loss in the financial statements. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain to the aforementioned reportable operating segment and geographical area.

13. Commitments and contingent liabilities

13.1 Commitments under service agreements

The Company had total minimum payments to be paid in the future under the service agreements as follows:

	(Unit: Million Baht)	
	31 January 2024	31 July 2023
	<hr/>	<hr/>
Payable:		
In up to 1 year	19.0	11.0
In over 1 year and up to 3 years	0.9	1.2

13.2 Capital commitments

As at 31 January 2024, the Company had capital commitments of Baht 137.2 million (31 July 2023: Baht 24.9 million) in respect of the acquisitions of buildings and building improvements, medical equipment and facility systems.

13.3 Guarantees

- a. As at 31 January 2024, the Company had credit facilities with a commercial bank for overdrafts of Baht 20 million and short-term loans of Baht 10 million (31 July 2023: Credit facilities with a commercial bank for overdrafts of Baht 20 million and short-term loans of Baht 10 million).
- b. As at 31 January 2024, the Company had outstanding bank guarantees of approximately Baht 6.4 million issued by the bank on behalf of the Company in respect of electricity use as required in the normal course of business. (31 July 2023: Baht 6.4 million).

14. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 14 March 2024.